● Recruiting

SKB445 for Injection in Solid Tumors

Condition: Advanced Solid Tumors · Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

PhasePhase 1

Planned participants126

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

This is a multicenter, open-label, multiple-dose dose finding and expansion study to evaluate the safety, tolerability, pharmacokinetic(PK) profile, and anti-tumor efficacy of SKB445 for injection in patients with advanced solid tumors.

This description comes directly from the study's public registry record.

Talk to the study team

Xin Li · 086-010-58302512 · lixin@kelun.com

Always discuss trial participation with your own doctor first.

Locations (1)

Cancer Hospital of Shandong First Medical University

Jinan, Shandong, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06826040